Skip to main content

Table 5 DIANA miRPath predicted KEGG pathways enriched in targeting by X chromosome miRNA differentially regulated in the early aftermath of MVC trauma in AA individuals who develop AP following MVC vs. those who recover

From: MicroRNA circulating in the early aftermath of motor vehicle collision predict persistent pain development and suggest a role for microRNA in sex-specific pain differences

KEGG pathway

P value

Example of predicted targets

Ubiquitin mediated proteolysis

2.15 × 10−10

 

Long-term potentiation

1.67 × 10−9

PRKCA*, CAMK4, GRIA1, PPP3CC, KRAS, CALM2*, GRIA2, PPP3CA, GRM1, RPS6KA3*, EP300*, GNAQ*

Axon guidance

1.32 × 10−7

GSK3B*, ABLIM3, SEMA5A, EPHA5, ROCK2*, PAK7, ROBO2, SEMA3C*, SRGAP1*, PPP3CC, KRAS, EPHA7, PPP3CA, PTK2*, RASA1*, NFAT5*, EPHB4*, UNC5C, CFL2*, SEMA3D, SEMA3A*, PLXNC1*, EPHA4*, SEMA3E, UNC5D

ErbB signaling

7.04 × 10−7

 

Neurotrophin signaling

7.35 × 10−7

GSK3B, NTRK2*, CAMK4, CRK, SORT1*, NTRK3*, FRS2*, MAP3K1*, KRAS, CALM2*, JUN, MAPK8, SOS1*, RPS6KA3*, GAB1, AKT3*, CAMK2B, FOXO3, MAP2K1, PRDM4, RAP1B, MAP3K5

Insulin signaling

8.72 × 10−7

 

Dopaminergic synapse

1.56 × 10−6

FOS, GSK3B*, PRKCA*, PPP2R5E, PPP2R3A, PPP2R2C, CREB5, DRD1, GRIA1, PPP3CC, CALM2*, GRIA2, PPP3CA, MAPK8, PPP2R2A, SCN1A, PPP2R3C, GNAQ, PPP2CB, AKT3*, CAMK2B, PPP1CB, GRIA3

  1. * Denotes mRNA experimentally validated to interact with an miRNA from Table 2, as identified by TarBase v 7.0